| Project/Area Number |
26860312
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | Tokyo Metropolitan Institute of Medical Science |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HAYASHI Yukiko
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 新規肝硬変治療薬候補 / 脱線維化作用 / コラーゲン線維分解系 / マクロファージ / 好中球 / マトリックスメタロプロテアーゼ / 1細胞トランスクリプトーム解析 / コラーゲン線維合成系 |
|---|
| Outline of Final Research Achievements |
Chronic hepatitis C virus (HCV) infection is one of the major causes of serious liver diseases, including liver cirrhosis. There are no anti-fibrotic drugs with efficacy against liver cirrhosis. Wnt/β-catenin signaling has been implicated in the pathogenesis of a variety of tissue fibrosis. We showed that ICG-001 derivative, a selective inhibitor of β-catenin/CBP interaction, exhibits the anti-fibrotic activity on HCV-induced fibrosis. In the present study, we investigated the molecular mechanism of the compound using HCV transgenic mouse model. Administration of ICG-001 derivative for 6 weeks led to increased levels of matrix metalloproteinase (MMP)-8, which was shown with mRNA and protein expression, enzymatic activities. The induced intrahepatic neutrophils and macrophages/monocytes were identified as the source of MMP-8. In conclusion, we hypothesize that induction of fibrolytic cells expressing MMP-8 contribute to the remission of fibrosis by ICG-001 derivative.
|
